<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931372</url>
  </required_header>
  <id_info>
    <org_study_id>PDY10433</org_study_id>
    <secondary_id>EudraCT:2008-003242-28</secondary_id>
    <nct_id>NCT00931372</nct_id>
  </id_info>
  <brief_title>Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Restoration of First Phase Insulin Release in Subjects With Type 2 Diabetes Mellitus With Subcutaneous Injection of 20 µg AVE0010 in a Double-blind, Randomized, Placebo-controlled, Two-way Cross Over Intravenous Glucose Challenge Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil GmbH, Neuss, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase
      and improves second phase insulin response in subjects with diabetes mellitus type 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin secretion curve</measure>
    <time_frame>within 10 minutes after I.V. glucose challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin secretion curve</measure>
    <time_frame>within 10 to 120 minutes after I.V. glucose challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sequence 1: AVE0010/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: lixisenatide 20 µg in 200 µL, one single dose
Period 2: placebo 200 µL, one single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: Placebo/AVE0010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: placebo 200 µL, one single dose
Period 2: lixisenatide 20 µg in 200 µL, one single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Solution for subcutaneous injection 100 µg/mL</description>
    <arm_group_label>Sequence 1: AVE0010/Placebo</arm_group_label>
    <arm_group_label>Sequence 2: Placebo/AVE0010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Sequence 1: AVE0010/Placebo</arm_group_label>
    <arm_group_label>Sequence 2: Placebo/AVE0010</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with type 2 diabetes mellitus on diet and exercise
             with/without metformin

          -  HbA1c&gt;=6,0 % and &lt;=8,5 % at screening

          -  BMI 25 to 35 kg/m²

          -  155&gt;=BP systolic &gt;=90 mmHg

          -  100&gt;=BP diastolic&gt;=45 mmHg

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph KAPITZA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH, Neuss, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin release</keyword>
  <keyword>Diabetes mellitus type 2</keyword>
  <keyword>GLP-1 agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

